Focus on Diabetes Care

Back to articles

Sulfonylureas as second-line agents increase the risk of adverse outcomes

KEY POINT

Adding sulfonylurea to metformin therapy or switching metformin to a sulfonylurea in patients with type 2 diabetes resulted in an increased risk of myocardial infarction (MI), all-cause mortality, and severe hypoglycemia compared with metformin monotherapy, according to results of an observational study published in BMJ.

SOURCES

Douros A, et al. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: Population based cohort study. BMJ. 2018;[Epub ahead of print]. 

D’Agostino L, et al. Sulfonylureas as second line treatment for type 2 diabetes. BMJ. 2018;[Epub ahead of print]. 

American Diabetes Association. Standards of Medical Care in Diabetes–2018. Accessed August 10, 2018.